Alternatives to clopidogrel for acute coronary syndromes: Prasugrel or ticagrelor?

Giuseppe Biondi-Zoccai, Marzia Lotrionte, Fiorenzo Gaita

Giuseppe Biondi-Zoccai, Marzia Lotrionte, Fiorenzo Gaita, Division of Cardiology, University of Turin, San Giovanni Battista “Molinette” Hospital, 10126 Turin, Italy; Unit for Heart Failure and Cardiac Rehabilitation, Catholic University, 00136 Rome, Italy

Author contributions: Biondi-Zoccai G conceived and drafted the manuscript; Lotrionte M and Gaita F provided critical comments to the manuscript and final approval.

Correspondence to: Dr. Giuseppe Biondi-Zoccai, Division of Cardiology, University of Turin, San Giovanni Battista “Molinette” Hospital, Corso Bramante 88-90, 10126 Turin, Italy. gbiondizoccai@gmail.com

Telephone: +39-11-6334195 Fax: +39-11-6967053
Received: May 24, 2010 Revised: June 1, 2010 Accepted: June 8, 2010 Published online: June 26, 2010

Abstract

Clopidogrel is a mainstay in the treatment of patients with acute coronary syndromes or those receiving endovascular prostheses. However, its efficacy has been challenged in the recent past by studies suggesting variable individual responsiveness and by new, more potent competitors, such as prasugrel and ticagrelor. But what is the actual body of evidence in support of clopidogrel? Is there any dark side of the moon? What is the role of prasugrel, which has already been approved in Europe and in the United States? And what will be the future role of ticagrelor, when approved for routine clinical practice? We hereby concisely summarize the scope of this clinical choice, providing arguments in favor and against each of the three antiplatelet agents: clopidogrel, prasugrel, and ticagrelor.

© 2010 Baishideng. All rights reserved.

Key words: Acute coronary syndrome; Clopidogrel; Prasugrel; Ticagrelor

Peer reviewers: Shinji Satoh, MD, PhD, Department of Cardiology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyo-hama, Chuo-ku, Fukuoka 810-8563, Japan; Ming-Jui Hung, MD, Cardiology Section, Department of Medicine, Chang Gung Memorial Hospital at Keelung, Chang Gung University College of Medicine, 222 Mai-Chin Road, Keelung City 20401, Taiwan, China; Nadezda Bylova, MD, PhD, Internal Disease, Russian State Medical University, 13, 25,Pavlovskaya str., Moscow, 115093, Russia

THE WELL-KNOWN PAST: CLOPIDOGREL

The crucial role of clopidogrel in association with aspirin in patients with acute coronary syndromes (ACS) is testified by the fact that this drug is among the best selling drugs worldwide, together with statins, proton-pump inhibitors, and angiotensin-Ⅱ receptor antagonists.

Clopidogrel is a thienopyridine which selectively and irreversibly inhibits the platelet adenosine 5’-diphosphate (ADP) P2Y12 receptor, providing synergistic inhibitory effects on platelet aggregation. Several studies strongly support the favorable risk-benefit balance of clopidogrel in ACS patients managed conservatively as well as invasively, and the most important of these is the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial, which randomly assigned 12,562 patients with ACS to receive clopidogrel (300 mg loading followed by 75 mg once daily) or placebo in addition to aspirin for 3 to 12 mo[1]. As the devil is often in the details, it is timely to review the main findings of this study. After an average follow-up of 9 mo, the composite event of death from cardiovascular causes, myocardial infarction or stroke occurred in 9.3% vs 11.4%, respectively (P < 0.001), a difference largely driven by significantly fewer myocardial infarctions in those treated with clopidogrel (5.2% vs 6.7%, P < 0.001). Conversely, the number of deaths from
cardiovascular causes or stroke, when analyzed individually, was not significantly different in the clopidogrel vs placebo group (5.1% vs 5.5%, P = 0.3 and 1.2% vs 1.4%, P = 0.4, respectively), a key negative finding for the interpretation of more recent trials. In addition, there were significantly more protocol-defined major bleedings in the clopidogrel group (3.7% vs 2.7%, P = 0.001), despite similar rates of major bleeding defined according to the Thrombolysis in Myocardial Infarction (TIMI) trial (1.1% vs 1.2%, P = 0.7) or major bleeding related to coronary artery bypass grafting (CABG, 1.3% vs 1.1%, P = 0.5).

Clopidogrel is also beneficial in patients with acute ST-elevation myocardial infarction (STEMI) managed with thrombolysis, as reported by the Clopidogrel as Adjunctive Reperfusion Therapy-TIMI 28 study and the Clopidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) [5,6]. Finally, interventional cardiologists and all endovascular specialists exploit daily the antiplatelet efficacy of clopidogrel in preparation and after deployment of metallic endovascular prostheses, such as stent. Narrow therapeutic window and need for frequent monitoring (warfarin) translates in higher incidence of bleeding complications.

### Table 1 Alternatives to clopidogrel for patients with acute coronary syndromes

| Drug       | Main features                                                                 | Pros                                                                 | Cons                                                                 |
|------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Clopidogrel| Phosphodiesterase inhibitor with antiplatelet and antirestenotic effects, also indicated for the medical treatment of claudication | Different mechanism of action translates into increased antithrombotic efficacy when used in combination with aspirin and a thienopyridine | Tolerability limited by gastro-intestinal side effects in up to 20% of patients |
| Oral anticoagulants | Several agents directly or indirectly inhibiting the coagulation process, including warfarin and dabigatran | Different mechanism of action translates into increased antithrombotic efficacy when used in combination with aspirin | Specificity for the coagulation process translates into lower efficacy on thrombotic processes largely dependent on platelets (such as stent thrombosis). Narrow therapeutic window and need for frequent monitoring (warfarin) translates in higher incidence of bleeding complications |
| Prasugrel  | Third-generation thienopyridine irreversibly inhibiting the P2Y12 receptor, with quicker, more consistent and more potent action than clopidogrel | Potency and consistency of effect enable homogeneous and nearly complete platelet aggregation inhibition in most patients, with ensuing benefits on myocardial infarction and stent thrombosis | Greater potency may translate into bleeding risk overcoming ischemic benefits in those at moderate or high bleeding risk, such as the elderly and those with previous stroke or transient ischemic attack |
| Ticagrelor | Non-thienopyridine agent reversibly inhibiting the P2Y12 receptor, with quicker, more consistent, and more potent action, but shorter half-life than clopidogrel | Direct action translates into quicker onset of action and lack of interaction with drugs metabolized by cytochrome P450, such as proton pump inhibitors | Shorter half-life may translate into greater risk of thrombotic recurrences in case of non-compliance |
| Ticlopidine| First-generation thienopyridine irreversibly inhibiting the P2Y12 receptor, with longer half-life than clopidogrel | Limited cross-unresponsiveness translates into potential role in those lacking complete response to clopidogrel. Off-patient status translates into low cost | Lower tolerability with frequent gastro-intestinal adverse effects. Rarely but significantly associated with life-threatening agranulocytosis and thrombotic thrombocytopenic purpura |

### THE PRESENT: PRASUGREL

Prasugrel is a thienopyridine ADP receptor inhibitor, which irreversibly binds to the P2Y12 receptor. In comparison to clopidogrel, prasugrel acts more quickly, more consistently, more potently, and has been shown to be best in pharmacokinetics studies clopidogrel, even when the latter is administered in high loading doses such as 600 or 900 mg. The pivotal trial appraising the role of prasugrel in patients with ACS, including STEMI, is the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-TRITON-TIMI 38 [3]. In this randomized study, including 13 608 patients treated with a 60 mg loading dose and a 10 mg daily maintenance dose of prasugrel or a 300 mg loading dose and a 75 mg daily maintenance dose of clopidogrel for 6 to 15 mo, prasugrel proved more effective than clopidogrel in reducing the risk of death from cardiovascular causes, myocardial infarction, or stroke (9.9% vs 12.1%, P < 0.001), an effect mainly driven by reduction in myocardial infarctions (7.3% vs 9.5%, P < 0.001), and those treated with implantable cardiovascular devices, clopidogrel has recently been challenged by more potent and, in selected cases, equally safe, antithrombotic agents (Table 1). Besides oral anticoagulants, such as warfarin and the more recent dabigatran [9], and niche agents, such as cilostazol and ticlopidine [10,11], the most promising alternatives to clopidogrel in those with background aspirin therapy are prasugrel and ticagrelor.
actually often qualifying for stent thrombosis (1.1% vs 2.4%, $P < 0.001$). Indeed, the authors reported similar rates of death from any cause (3.0% vs 3.2%, $P = 0.6$), death from cardiovascular causes (2.1% vs 2.4%, $P = 0.3$), and stroke (1.0% vs 1.0%, $P = 0.9$) in the prasugrel vs clopidogrel groups. This remarkable antithrombotic effects were however offset by an increased bleeding risk, clustering particularly in the elderly and those with previous stroke or transient ischemic attack, as major bleeding occurred in 2.5% of those treated with prasugrel vs 1.7% of those treated with clopidogrel ($P = 0.001$), with the excess risk mainly due to CABG-related major bleeding (0.4% vs 0.1%, $P = 0.001$).

THE FUTURE: TICAGRELOR

Ticagrelor is instead a reversible inhibitor of platelet P2Y12-subtype ADP receptor, and thus does not belong to the thienopyridine family. Given its reversible binding to the target receptor and shorter half-life, ticagrelor holds the promise of a larger therapeutic window, especially for patients who might end up undergoing CABG early after drug administration. Indeed, the pivotal Platelet Inhibition and Patient Outcomes (PLATO) study randomized 18,624 patients with ACS to 180 mg loading dose, 90 mg twice daily thereafter of ticagrelor vs 300-600 mg loading dose, 75 mg daily thereafter of clopidogrel for 12 months. The risk of death from vascular causes, myocardial infarction, or stroke was significantly reduced by ticagrelor (9.8% vs 11.7%, $P < 0.001$), an effect stemming from consistent reductions in the risk of death from all causes (4.5% vs 5.9%, $P < 0.001$), death from vascular causes (4.0% vs 5.1%, $P = 0.001$), and myocardial infarction (5.8% vs 6.9%, $P = 0.005$), including stent thrombosis (1.3% vs 1.9%, $P = 0.009$). Stroke occurred with similar frequency in the ticagrelor and clopidogrel groups (1.5% vs 1.3%, $P = 0.2$), similarly to CABG-related major bleeding (4.8% vs 5.2%, $P = 0.3$) and all TIMI major bleeding (7.1% vs 6.9%, $P = 0.7$). However, non-CABG related bleeding still occurred more frequently in the ticagrelor group (2.8% vs 2.2%, $P = 0.030$).

RECONCILING THE EVIDENCE

Awaiting head-to-head randomized trials of ticagrelor vs prasugrel, it is difficult to identify which of these two agents offers the best risk-benefit balance to overcome the limitations of clopidogrel. A superficial review of the PLATO and TRITON-TIMI 38 trials would suggest that ticagrelor is the winner in most patients, including those at moderately increased bleeding risk, given the significant mortality benefit and the similar risk of CABG-related major bleeding. However, formal interaction tests would probably provide more precise adjusted indirect comparison estimates, enabling decision makers to select the most appropriate agent for each individual clinical case, in order to maximize safety but also efficacy.$^{[11,13]}$ Indeed, the dramatic reduction in the risk of stent thrombosis, especially drug-eluting stent thrombosis, achieved by prasugrel (0.8% vs 2.3%, $P < 0.001$), would suggest that this agent should probably be considered the first-line one in those at higher risk of thrombotic events$^{[10]}$, such as diabetics and/or those with diffuse coronary stenting$^{[17]}$.

ACKNOWLEDGMENTS

Dr. Biondi-Zoccai has consulted for Astra Zeneca (ticagrelor), Bristol Myers Squibb and Sanofi-Aventis (clopidogrel), Daichii Sankyo and Eli Lilly (prasugrel).

REFERENCES

1 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KF. Effects of ticagrelor in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502

2 Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claesys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189

3 Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Cullins R, Liu LS. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621

4 Lotriente M, Biondi-Zoccai GG, Agostoni P, Abbate A, Angiolillo DJ, Valgimigli M, Moretti C, Meliga E, Cuisset T, Alessi MC, Montalescot G, Collet JP, Di Sciascio G, Waksman R, Testa L, Sangiorgi G, Laudito A, Trevi GP, Sheiban I. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007; 100: 1199-1206

5 Bollati M, Moretti C, Omede P, Sciuto F, Grosso Marra W, Palumbo L, Biondi-Zoccai G, Sheiban I. Percutaneous aortic valve replacement in two cases at high surgical risk: procedural details and implications for patient selection. Minerva Cardioangiol 2009; 57: 131-136

6 Butera G, Biondi-Zoccai GG, Carminati M, Caputi L, Usai S, Bussone G, Meola G, Delogu AB, Sheiban I, Sangiorgi G. Systematic review and meta-analysis of currently available clinical evidence on migraine and patent foramen ovale ovale percutaneous closure: much ado about nothing? Catheter Cardiovasc Interv 2010; 75: 494-504

7 Miwa K, Kambara H, Kawai C. Variant angina aggravated by aspirin. Lancet 1979; 2: 1382

8 Kounis NG, Zavras GM. Histamine-induced coronary artery spasm: the concept of allergic angina. Br J Clin Pract 1991; 45: 121-128

9 Lotriente M, Castagno D, Agostoni P, Abbate A, Sangiorgi G, Sheiban I, Biondi-Zoccai GG. Long-term effect of chronic oral anticoagulation: focus on coronary artery disease. Future Cardiol 2009; 5: 259-271

10 Biondi-Zoccai GG, Lotriente M, Anselmino M, Moretti C, Agostoni P, Testa L, Abbate A, Cosgrave J, Laudito A, Trevi GP, Sheiban I. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 2008; 155: 1081-1089

11 Biondi-Zoccai GG, Agostoni P, Sangiorgi GM, Iakovou I, Antoniucci D, Grube E, Tamburino C, Di Mario C, Reimers B, Michiev I, Goktekin O, Aiolfi F, Chieffo A, Cosgrove J, Tassanawiwat W, Colombo A. Comparison of ticlopidine vs. clopidogrel in addition to aspirin after pacchexel-eluting
stent implantation: insights from the TRUE (Taxus in Real-life Usage Evaluation) Study. *Int J Cardiol* 2006; **108**: 406-407

12 *Wiviott SD*, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2007; **357**: 2001-2015

13 *Wallentin L*, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thomsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009; **361**: 1045-1057

14 *Biondi-Zoccai GG*, Agostoni P, Abbate A, Testa L, Burzotta F, Crea F, Colombo A. Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials. *Int J Cardiol* 2005; **100**: 119-123

15 *Biondi-Zoccai GG*, Lotrionte M, Abbate A, Valgimigli M, Testa L, Burzotta F, Crea F, Agostoni P. Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients. *Int J Cardiol* 2007; **114**: 104-105

16 *Testa L*, Bhindi R, Van Gaal WJ, Latini RA, Pizzocri S, Lanotte S, Biondi Zoccai GG, Valgimigli M, Laudisa ML, Brambilla N, Banning AP, Bedogni F. What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. *QJM* 2010; **103**: 367-377

17 *Wiviott SD*, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. *Lancet* 2008; **371**: 1353-1363

S- Editor Cheng JX  L- Editor Negro F  E- Editor Zheng XM